Document:

<PAGE>

                                                                    Exhibit 10.3

     THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT
     BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
     "SECURITIES ACT"), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES
     OR ANY OTHER JURISDICTION. THE SECURITIES REPRESENTED HEREBY MAY NOT BE
     OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
     STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS UNLESS
     OFFERED, SOLD OR TRANSFERRED PURSUANT TO AN AVAILABLE EXEMPTION FROM THE
     REGISTRATION REQUIREMENTS OF THOSE LAWS.

                                          Right to Purchase __________ Shares of
                                         Common Stock, par value $.001 per share

March 24, 2006

                           IDERA PHARMACEUTICALS, INC.
                             STOCK PURCHASE WARRANT

     THIS CERTIFIES THAT, for value received, _________________________, or its
registered assigns, is entitled to purchase from Idera Pharmaceuticals, Inc., a
corporation organized under the laws of the State of Delaware (the "COMPANY"),
at any time or from time to time during the period specified in Section 2
hereof, _______________________ (__________) fully paid and nonassessable shares
of the Company's common stock, par value $0.001 per share (the "COMMON STOCK"),
at an exercise price per share (the "EXERCISE PRICE") equal to $0.65. The number
of shares of Common Stock purchasable hereunder (the "WARRANT SHARES") and the
Exercise Price are subject to adjustment as provided in Section 4 hereof. The
term "WARRANTS" means this Warrant and the other warrants of the Company issued
pursuant to that certain Common Stock Purchase Agreement, dated as of March 24,
2006, by and among the Company and the other signatories thereto (the "STOCK
PURCHASE AGREEMENT").

     This Warrant is subject to the following terms, provisions and conditions:

     1. MANNER OF EXERCISE; ISSUANCE OF CERTIFICATES; PAYMENT FOR SHARES.
Subject to the provisions hereof, including, without limitation, the limitations
contained in Section 7 hereof, this Warrant may be exercised by the holder
hereof, in whole or in part, by the surrender of this Warrant, together with a
completed exercise agreement in the form attached hereto (the "EXERCISE
AGREEMENT"), to the Company during normal business hours on any business day at
the Company's principal executive offices (or such other office or agency of the
Company as it may designate by notice to the holder hereof), and upon payment to
the Company in cash, by certified or official bank check or by wire transfer for
the account of the Company, of the Exercise Price for the Warrant Shares
specified in the Exercise Agreement. The Warrant Shares so purchased shall be
deemed to be issued to the holder hereof or such holder's designee, as the
record owner of such shares, as of the close of business on the date on which
this Warrant shall have been surrendered, the completed Exercise Agreement shall
have been delivered, and payment shall have been made for such shares as set
forth above or, if such date is not a business

                                       1.

<PAGE>

date, on the next succeeding business date (such date being referred to as the
"Exercise Date"). The Warrant Shares so purchased, representing the aggregate
number of shares specified in the Exercise Agreement, shall be delivered to the
holder hereof as soon as possible, and in no event more than ten (10) days,
after the Exercise Date (the "DELIVERY PERIOD"). If the Company's transfer agent
is participating in the Depository Trust Company ("DTC") Fast Automated
Securities Transfer program, and so long as the certificates therefor are to be
delivered without a legend, the Company shall cause its transfer agent to
electronically transmit the Warrant Shares so purchased to the holder by
crediting the account of the holder or its nominee with DTC through its Deposit
Withdrawal Agent Commission system ("DTC TRANSFER"). If the aforementioned
conditions to a DTC Transfer are not satisfied, the Company shall deliver to the
holder physical certificates representing the Warrant Shares so purchased.
Further, the holder may instruct the Company to deliver to the holder physical
certificates representing the Warrant Shares so purchased in lieu of delivering
such shares by way of DTC Transfer. Any certificates so delivered shall be in
such denominations as may be reasonably requested by the holder hereof, shall be
registered in the name of such holder or such other name as shall be designated
by such holder (upon payment by the holder of any applicable transfer or
withholding taxes) and shall bear a restrictive legend as set forth in Section
8.2 of the Stock Purchase Agreement unless the conditions set forth in Section
8.3 of the Stock Purchase Agreement are met in connection with the exercise. If
this Warrant shall have been exercised only in part, then the Company shall, at
its expense, at the time of delivery of such certificates, deliver to the holder
a new Warrant representing the number of shares with respect to which this
Warrant shall not then have been exercised.

     If, at any time, a holder of this Warrant submits this Warrant, an Exercise
Agreement and payment to the Company of the Exercise Price for each of the
Warrant Shares specified in the Exercise Agreement, and the Company fails for
any reason to deliver, on or prior to the fourth business day following the
expiration of the Delivery Period for such exercise, the number of Warrant
Shares to which the holder is entitled upon such exercise (an "EXERCISE
DEFAULT"), then the Company shall pay to the holder, as liquidated damages and
not a penalty for such Exercise Default (which remedy shall constitute the
holder's exclusive monetary remedy), payments ("EXERCISE DEFAULT PAYMENTS") for
an Exercise Default in the amount of (a) (N/365), multiplied by (b) the amount
by which the Market Price (as defined in Section 4(j) hereof) on the Exercise
Date exceeds the Exercise Price in respect of such Warrant Shares, multiplied by
(c) the number of shares of Common Stock the Company failed to so deliver in
such Exercise Default, multiplied by (d) .12, where N = the number of days from
the last day of the Delivery Period to the date that the Company delivers the
number of Warrant Shares to which the holder was entitled upon such exercise.
The accrued Exercise Default Payment for each calendar month shall be paid in
cash to holder by the fifth day of the month following the month in which it has
accrued.

     Nothing herein shall limit the holder's right to pursue actual damages for
the Company's failure to maintain a sufficient number of authorized shares of
Common Stock as required pursuant to the terms of Section 3(b) hereof, and the
holder shall have the right to pursue all remedies available at law or in equity
(including a decree of specific performance and/or injunctive relief).

                                       2.

<PAGE>

     2. PERIOD OF EXERCISE. This Warrant is immediately exercisable, at any time
or from time to time on or after the date six months following the date of
initial issuance of this Warrant (the "ISSUE DATE") and before 5:00 p.m., New
York City time, on the fifth anniversary of the commencement of such five year
period (the "EXERCISE PERIOD"). The Exercise Period shall automatically be
extended by one (1) day for each day on which the Company does not have a number
of shares of Common Stock reserved for issuance upon exercise hereof at least
equal to the number of shares of Common Stock issuable upon exercise hereof.

     3. CERTAIN AGREEMENTS OF THE COMPANY. The Company hereby covenants and
agrees as follows:

          (A) SHARES TO BE FULLY PAID. The Warrant Shares have been duly
authorized and, when issued, delivered and paid for in the manner set forth in
this Warrant, will be duly authorized, validly issued, fully paid and
nonassessable and free and clear of all pledges, liens, and encumbrances imposed
by the Company (other than restrictions on transfer under state and/or federal
securities laws).

          (B) RESERVATION OF SHARES. During the Exercise Period, the Company
shall at all times have authorized, and reserved for the purpose of issuance
upon exercise of this Warrant, a sufficient number of shares of Common Stock to
provide for the exercise in full of this Warrant.

          (C) LISTING. The Company acknowledges its obligations under Section
5.6 of the Stock Purchaser Agreement.

          (D) CERTAIN ACTIONS PROHIBITED. The Company will not, by amendment of
its charter or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities, or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms to be
observed or performed by it hereunder, but will at all times in good faith
assist in the carrying out of all the provisions of this Warrant and in the
taking of all such action as may reasonably be requested by the holder of this
Warrant in order to protect the rights of the holder against impairment,
consistent with the tenor and purpose of this Warrant. Without limiting the
generality of the foregoing, the Company (i) will not increase the par value of
any shares of Common Stock receivable upon the exercise of this Warrant above
the Exercise Price then in effect, and (ii) will take all such actions as may be
necessary or appropriate in order that the Company may validly and legally issue
fully paid and nonassessable shares of Common Stock upon the exercise of this
Warrant.

          (E) SUCCESSORS AND ASSIGNS. This Warrant will be binding upon any
entity succeeding to the Company by merger or consolidation.

     4. ANTIDILUTION PROVISIONS. During the Exercise Period, the Exercise Price
and the number of Warrant Shares issuable hereunder shall be subject to
adjustment from time to time as provided in this Section 4.

          (A) SUBDIVISION OR COMBINATION OF COMMON STOCK. If the Company, at any
time during the Exercise Period, subdivides (by any stock split, stock dividend,
recapitalization, reorganization, reclassification or otherwise) its shares of
Common Stock into a greater number

                                       3.

<PAGE>

of shares, then, after the date of record for effecting such subdivision, the
Exercise Price in effect immediately prior to such subdivision will be
proportionately reduced. If the Company, at any time during the Exercise Period,
combines (by reverse stock split, recapitalization, reorganization,
reclassification or otherwise) its shares of Common Stock into a smaller number
of shares, then, after the date of record for effecting such combination, the
Exercise Price in effect immediately prior to such combination will be
proportionately increased.

          (B) ADJUSTMENT FOR CERTAIN DIVIDENDS AND DISTRIBUTIONS. In the event
the Company at any time, or from time to time after the date of this Warrant
shall make or issue, or fix a record date for the determination of holders of
Common Stock entitled to receive, a dividend or other distribution payable in
additional shares of Common Stock, then and in each such event the Exercise
Price then in effect immediately before such event shall be decreased as of the
time of such issuance or, in the event such a record date shall have been fixed,
as of the close of business on such record date, by multiplying the Exercise
Price then in effect by a fraction:

               (I) the numerator of which shall be the total number of shares of
Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date, and

               (II) the denominator of which shall be the total number of shares
of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date plus the number of shares
of Common Stock issuable in payment of such dividend or distribution;

provided, however, that if such record date shall have been fixed and such
dividend is not fully paid or if such distribution is not fully made on the date
fixed therefor, the Exercise Price shall be recomputed accordingly as of the
close of business on such record date and thereafter the Exercise Price shall be
adjusted pursuant to this paragraph as of the time of actual payment of such
dividends or distributions.

          (C) ADJUSTMENT IN NUMBER OF SHARES. Upon each adjustment of the
Exercise Price pursuant to the provisions of Section 4(a) and (b), the number of
shares of Common Stock issuable upon exercise of this Warrant at each such
Exercise Price shall be adjusted to an amount calculated by multiplying a number
equal to the Exercise Price in effect immediately prior to such adjustment by
the number of shares of Common Stock issuable upon exercise of this Warrant at
such Exercise Price immediately prior to such adjustment and dividing the
product so obtained by the adjusted Exercise Price.

          (D) ADJUSTMENT FOR REORGANIZATION. If there shall occur any
reorganization, recapitalization, reclassification, consolidation or merger
involving the Company in which the Common Stock is converted into or exchanged
for securities, cash or other property (other than a transaction covered by
subsections 4(a), 4(b) or 4(e)) (collectively, a "REORGANIZATION"), then,
following such Reorganization, the holder shall receive upon exercise hereof the
kind and amount of securities, cash or other property which the holder would
have been entitled to receive pursuant to such Reorganization if such holder had
exercised this Warrant immediately prior to such Reorganization. In any such
case, appropriate adjustment (as determined in good faith by

                                       4.

<PAGE>

the Company's Board of Directors shall be made in the application of the
provisions set forth herein with respect to the rights and interests thereafter
of the registered holder, to the end that the provisions set forth in this
Section 4 (including provisions with respect to changes in and other adjustments
of the Exercise Price) shall thereafter be applicable, as nearly as reasonably
may be, in relation to any securities, cash or other property thereafter
deliverable upon the exercise of this Warrant. The Company will not effect any
consolidations, merger or sale or conveyance unless prior to the consummation
thereof, the successor corporation (if other than the Company) assumes by
written instrument the obligations under this Warrant and the obligations to
deliver to the holder hereof such shares of stock, securities or assets as, in
accordance with the foregoing provisions, the holder may be entitled to acquire.

          (E) ADJUSTMENTS FOR OTHER DIVIDENDS AND DISTRIBUTIONS. In the event
the Company at any time, or from time to time after the date of this Warrant
shall make or issue, or fix a record date for the determination of holders of
Common Stock entitled to receive, a dividend or other distribution payable in
securities of the Company (other than shares of Common Stock) or in cash or
other property (other than regular cash dividends paid out of earnings or earned
surplus, determined in accordance with generally accepted accounting
principles), then and in each such event provision shall be made so that the
holder shall receive upon exercise hereof, in addition to the number of shares
of Common Stock issuable hereunder, the kind and amount of securities of the
Company, cash or other property which the holder would have been entitled to
receive had such holder exercised this Warrant immediately prior to the date of
such event and had the holder thereafter, during the Exercise Period, retained
any such securities receivable during such period, giving application to all
adjustments called for during such period under this Section 4 with respect to
the rights of the holder.

          (F) NOTICE OF ADJUSTMENT. Promptly following the occurrence of any
event which requires any adjustment of the Exercise Price, then, and in each
such case, the Company shall give notice thereof to the holder hereof, which
notice shall state the Exercise Price resulting from such adjustment and the
increase or decrease in the number of Warrant Shares purchasable at such price
upon exercise, setting forth in reasonable detail the method of calculation and
the facts upon which such calculation is based. Such calculation shall be
certified by the chief financial officer of the Company.

          (G) NO FRACTIONAL SHARES. No fractional shares of Common Stock are to
be issued upon the exercise of this Warrant, but the Company shall pay a cash
adjustment in respect of any fractional share which would otherwise be issuable
in an amount equal to the same fraction of the Market Price of a share of Common
Stock on the date of such exercise.

          (H) OTHER NOTICES. In case at any time:

          (I) the Company shall declare any dividend upon the Common Stock
payable in shares of stock of any class or make any other distribution (other
than dividends or distributions payable in cash out of retained earnings
consistent with the Company's past practices with respect to declaring dividends
and making distributions) to the holders of the Common Stock;

                                       5.

<PAGE>

               (II) the Company shall offer for subscription pro rata to the
holders of the Common Stock any additional shares of stock of any class or other
rights;

               (III) there shall be any capital reorganization of the Company,
or reclassification of the Common Stock, or consolidation or merger of the
Company with or into, or sale of all or substantially all of its assets to,
another corporation or entity; or

               (IV) there shall be a voluntary or involuntary dissolution,
liquidation or winding up of the Company;

then, in each such case, the Company shall give to the holder of this Warrant
(a) notice of the date or estimated date on which the books of the Company shall
close or a record shall be taken for determining the holders of Common Stock
entitled to receive any such dividend, distribution, or subscription rights or
for determining the holders of Common Stock entitled to vote in respect of any
such reorganization, reclassification, consolidation, merger, sale, dissolution,
liquidation or winding-up at least ten (10) days prior to the record date or the
date on which the Company's books are closed in respect thereto and (b) in the
case of any such reorganization, reclassification, consolidation, merger, sale,
dissolution, liquidation or winding-up, notice of the date (or, if not then
known, a reasonable estimate thereof by the Company) when the same shall take
place at least (20) days prior to such date. Such notice shall also specify the
date on which the holders of Common Stock shall be entitled to receive such
dividend, distribution, or subscription rights or to exchange their Common Stock
for stock or other securities or property deliverable upon such reorganization,
reclassification, consolidation, merger, sale, dissolution, liquidation, or
winding-up, as the case may be. Failure to give any such notice or any defect
therein shall not affect the validity of the proceedings referred to in clauses
(i), (ii), (iii) and (iv) above. Notwithstanding the foregoing, the Company
shall publicly disclose the substance of any notice delivered hereunder prior to
delivery of such notice to the holder hereof.

          (I) CERTAIN EVENTS. If, at any time during the Exercise Period, any
event occurs of the type contemplated by the adjustment provisions of this
Section 4 but not expressly provided for by such provisions, the Company will
give notice of such event as provided in Section 4(h) hereof, and the Company's
Board of Directors will make an appropriate adjustment in the Exercise Price and
the number of shares of Common Stock acquirable upon exercise of this Warrant at
each such Exercise Price so that the rights of the holder shall be neither
enhanced nor diminished by such event.

          (J) CERTAIN DEFINITIONS. "MARKET PRICE," as of any date, (i) means the
average of the closing prices for the shares of Common Stock as reported on the
American Stock Exchange by Bloomberg Financial Markets ("BLOOMBERG") for the ten
(10) consecutive business days immediately preceding such date, or (ii) if the
American Stock Exchange is not the principal trading market for the shares of
Common Stock, the average of the reported closing prices reported by Bloomberg
on the principal trading market for the Common Stock during the same period, or,
if there is no closing price for such period, the last sale price reported by
Bloomberg for such period, or (iii) if the foregoing do not apply, the last sale
price of such security in the over-the-counter market on the pink sheets or
bulletin board for such security as reported by Bloomberg, or if no sale price
is so reported for such security, the last closing price of such security as
reported by Bloomberg, or (iv) if market value cannot be calculated as of such

                                       6.

<PAGE>

date on any of the foregoing bases, the Market Price shall be deemed to be the
amount most recently determined by the Company's Board of Directors or an
authorized committee of the Company's Board of Directors to represent the fair
market value per share of the Common Stock (including without limitation a
determination for purposes of granting Common Stock options or issuing Common
Stock under any plan, agreement or arrangement with employees of the Company).
The manner of determining the Market Price of the Common Stock set forth in the
foregoing definition shall apply with respect to any other security in respect
of which a determination as to market value must be made hereunder.

     5. ISSUE TAX. The issuance of certificates for Warrant Shares upon the
exercise of this Warrant shall be made without charge to the holder of this
Warrant or such shares for any issuance tax or other costs in respect thereof,
provided that the Company shall not be required to pay any tax which may be
payable in respect of any transfer involved in the issuance and delivery of any
certificate in a name other than the holder of this Warrant.

     6. NO RIGHTS OR LIABILITIES AS A STOCKHOLDER. This Warrant shall not
entitle the holder hereof to any voting rights or other rights as a stockholder
of the Company. No provision of this Warrant, in the absence of affirmative
action by the holder hereof to purchase Warrant Shares, and no mere enumeration
herein of the rights or privileges of the holder hereof, shall give rise to any
liability of such holder for the Exercise Price or as a stockholder of the
Company, whether such liability is asserted by the Company or by creditors of
the Company.

     7. TRANSFER, EXCHANGE, REDEMPTION AND REPLACEMENT OF WARRANT.

          (A) RESTRICTION ON TRANSFER. This Warrant and the rights granted to
the holder hereof are transferable, in whole or in part, upon surrender of this
Warrant, together with a properly executed assignment in the form attached
hereto, at the office or agency of the Company referred to in Section 7(e)
below, provided, however, that any transfer or assignment shall be subject to
the conditions and provisions of Section 8.1 of the Stock Purchase Agreement.
Each transferee of this Warrant or any portion thereof shall be bound by the
selling restrictions set forth in Section 8.1 of the Stock Purchase Agreement,
which Section is incorporated herein by reference. Until due presentment for
registration of transfer on the books of the Company, the Company may treat the
registered holder hereof as the owner and holder hereof for all purposes, and
the Company shall not be affected by any notice to the contrary. Notwithstanding
anything to the contrary contained herein, the registration rights described in
Section 8 hereof are assignable only in accordance with the provisions of the
Registration Rights Agreement, dated as of March 24, 2006, by and between the
Company and the other signatories thereto (the "REGISTRATION RIGHTS AGREEMENT").

          (B) WARRANT EXCHANGEABLE FOR DIFFERENT DENOMINATIONS. This Warrant is
exchangeable, upon the surrender hereof by the holder hereof at the office or
agency of the Company referred to in Section 7(e) below, for a reasonable number
of new Warrants of like tenor of different denominations representing in the
aggregate the right to purchase the number of shares of Common Stock which may
be purchased hereunder, each of such new Warrants to represent the right to
purchase such number of shares (at the Exercise Price therefor) as shall be
designated by the holder hereof at the time of such surrender.

                                       7.

<PAGE>

          (C) REPLACEMENT OF WARRANT. Upon receipt of evidence reasonably
satisfactory to the Company of the loss, theft, destruction, or mutilation of
this Warrant and, in the case of any such loss, theft, or destruction, upon
delivery of an indemnity agreement reasonably satisfactory in form and amount to
the Company, or, in the case of any such mutilation, upon surrender and
cancellation of this Warrant, the Company, at its expense, will execute and
deliver, in lieu thereof, a new Warrant of like tenor.

          (D) CANCELLATION; PAYMENT OF EXPENSES. Upon the surrender of this
Warrant in connection with any transfer, exchange, or replacement as provided in
this Section 7, this Warrant shall be promptly canceled by the Company. In the
event that one party breaches this Warrant, such party shall pay all of the
other party's costs and expenses (including reasonable legal fees) incurred by
such other party in connection with the enforcement of such other party's rights
hereunder.

          (E) WARRANT REGISTER. The Company shall maintain, at its principal
executive offices (or such other office or agency of the Company as it may
designate by notice to the holder hereof), a register for this Warrant, in which
the Company shall record the name and address of the person in whose name this
Warrant has been issued, as well as the name and address of each transferee and
each prior owner of this Warrant.

     8. REGISTRATION RIGHTS. The initial holder of this Warrant (and certain
assignees thereof) is entitled to the benefit of such registration rights in
respect of the Warrant Shares as are set forth in the Registration Rights
Agreement, including the right to assign such rights to certain assignees, to
the extent permitted thereunder.

     9. NOTICES. All notices and other communications from the Company to the
registered holder of this Warrant in connection herewith shall be mailed by
certified or registered mail, postage prepaid, or sent via a reputable overnight
courier service to the address last furnished to the Company in writing by the
Registered Holder. All notices and other communications from the registered
holder to the Company in connection herewith shall be mailed by certified or
registered mail, postage prepaid, or sent via a reputable overnight courier
service to the Company at its principal office set forth:

          Idera Pharmaceuticals, Inc.
          345 Vassar Street
          Cambridge, MA 02139
          Telephone: (617) 679-5500
          Attn: Chief Executive Officer

     with a copy simultaneously transmitted by like means to:

          Wilmer Cutler Pickering Hale and Dorr LLP
          60 State Street
          Boston, Massachusetts 02109
          Attn: Stuart Falber
          Facsimile: (617) 526-5000

                                       8.

<PAGE>

If the Company should at any time change the location of its principal office to
a place other than as set forth below, it shall give prompt written notice to
the registered holder and thereafter all references in this Warrant to the
location of its principal office at the particular time shall be as so specified
in such notice. All such notices and communications shall be deemed delivered
(i) upon delivery to the party to be notified, (ii) when received by confirmed
facsimile, or (iii) one (1) business day after deposit with a nationally
recognized overnight carrier, specifying next business day delivery, with
written verification of receipt.

     10. GOVERNING LAW; JURISDICTION. This Warrant shall be governed by and
construed in accordance with the laws of the State of New York. The Company and
the holder each irrevocably consents to the jurisdiction of the United States
federal courts and state courts located in the State of New York, Borough of
Manhattan, in any suit or proceeding based on or arising under this Warrant and
irrevocably agrees that all claims in respect of such suit or proceeding may be
determined in such courts. The Company and the holder each irrevocably waives
any objection to the laying of venue and the defense of an inconvenient forum to
the maintenance of such suit or proceeding. Each party further agrees that
service of process upon such party mailed by certified or registered mail shall
be deemed in every respect effective service of process upon such party in any
such suit or proceeding. Nothing herein shall affect a party's right to serve
process in any other manner permitted by law.

     11. MISCELLANEOUS.

          (A) AMENDMENT OR WAIVER. This Warrant and any provision hereof may
only be amended, and any provision of this Warrant may only be waived, by an
instrument in writing signed by the Company and the holder hereof.

          (B) DESCRIPTIVE HEADINGS. The descriptive headings of the several
Sections of this Warrant are inserted for purposes of reference only, and shall
not affect the meaning or construction of any of the provisions hereof.

          (C) TRADING DAY. For purposes of this Warrant, the term "trading day"
means any day on which the principal United States securities exchange or
trading market where the Common Stock is then listed is open for trading.

          (D) REDEMPTION OF WARRANT BY COMPANY.

               (I) At any time after March 24, 2010, provided that (x) all
shares of Common Stock issuable upon exercise of the Warrants are then (A)
authorized and reserved for issuance (B) registered under the Securities Act of
1933, as amended, for resale by the holders of the Warrants, and (C) eligible to
be traded on a Permitted Exchange (as defined in the Stock Purchase Agreement),
and (y) the volume weighted average of the closing prices of the Common Stock as
reported on the applicable Permitted Exchange of the Common Stock exceeds 300%
of the Exercise Price as in effect on the Issue Date for fifteen (15) or more
consecutive trading days immediately prior to the delivery by the Company of a
Redemption Notice (as defined below), the Company may elect, upon delivery of at
least twenty (20) days' prior written notice (the "REDEMPTION NOTICE") to the
holder hereof, to redeem all or a portion of the Warrants for a redemption
amount equal to the number of Warrant Shares issuable upon the exercise of all
or a

                                       9.

<PAGE>

portion of this Warrant that is being redeemed multiplied by $0.01 (the
"REDEMPTION AMOUNT"). In the event the Company elects to redeem only some of the
outstanding Warrants pursuant to this Section 11(d), such Warrants shall be
redeemed pro rata among all the holders of the Warrants based upon the
percentage of Warrants held by such holders against the total outstanding
Warrants.

               (II) The Company may not deliver a Notice of Redemption unless on
or prior to the date of delivery of a Notice of Redemption, the Company shall
have segregated on the books and records of the Company an amount of cash
sufficient to pay all amounts to which holders of the Warrants that are being
redeemed are entitled pursuant to Section 11(d)(i). Any Notice of Redemption
delivered shall be irrevocable and shall be accompanied by a statement executed
by a duly authorized officer of the Company.

               (III) The Redemption Amount shall be paid to the holder within
three (3) business days of the date of redemption set forth in the Notice of
Redemption; provided, however, that the Company shall not be obligated to
deliver any portion of the Redemption Amount until either this Warrant is
delivered to the Company or the holder notifies the Company that the Warrant has
been lost, stolen or destroyed and delivers the documentation in accordance with
Section 7(c) hereof. In the event only a portion of this Warrant is being
redeemed, the Company shall issue, at its expense, a new Warrant representing
the number of shares with respect to which this Warrant shall not then have been
redeemed or exercised.

               (IV) Notwithstanding the delivery of a Redemption Notice, the
holder may exercise all or a portion of this Warrant subject to such Redemption
Notice by the delivery prior to the date of redemption set forth in such notice
of an Exercise Agreement pursuant to the procedures set forth in Section 1.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       10.

<PAGE>

     IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by its
duly authorized officer.

                                        IDERA PHARMACEUTICALS, INC.

                                        By:
                                            ------------------------------------
                                        Name:
                                              ----------------------------------
                                        Title:
                                               ---------------------------------

                                       11.

<PAGE>

                           FORM OF EXERCISE AGREEMENT

         (TO BE EXECUTED BY THE HOLDER IN ORDER TO EXERCISE THE WARRANT)

To:  Idera Pharmaceuticals, Inc.
     345 Vassar Street
     Cambridge, MA 92139
     Telephone: (617) 679-5500
     Attn: Chief Executive Officer

     The undersigned hereby irrevocably exercises the right to purchase
_____________ shares of the Common Stock of Idera Pharmaceuticals, Inc., a
corporation organized under the laws of the State of Delaware (the "COMPANY"),
evidenced by the attached Warrant, and herewith makes payment of the Exercise
Price with respect to such shares in full, all in accordance with the conditions
and provisions of said Warrant.

     The undersigned agrees not to offer, sell, transfer or otherwise dispose of
any Common Stock obtained on exercise of the Warrant, except under circumstances
that will not result in a violation of the Securities Act of 1933, as amended,
or any state securities laws.

[ ]  The undersigned requests that the Company cause its transfer agent to
     electronically transmit the Common Stock issuable pursuant to this Exercise
     Agreement to the account of the undersigned or its nominee (which is
     _________________) with DTC through its Deposit Withdrawal Agent Commission
     System ("DTC TRANSFER"), provided that such transfer agent participates in
     the DTC Fast Automated Securities Transfer program and the certificates are
     to be delivered without a legend.

[ ]  In lieu of receiving the shares of Common Stock issuable pursuant to this
     Exercise Agreement by way of DTC Transfer, the undersigned hereby requests
     that the Company cause its transfer agent to issue and deliver to the
     undersigned physical certificates representing such shares of Common Stock.

     The undersigned requests that a Warrant representing any unexercised
portion hereof be issued, pursuant to the Warrant, in the name of the Holder and
delivered to the undersigned at the address set forth below:

Dated:
       ------------------------------   ----------------------------------------
                                        Signature of Holder

                                        ----------------------------------------
                                        Name of Holder (Print)

                                        Address:

                                        ----------------------------------------

                                        ----------------------------------------

                                        ----------------------------------------

<PAGE>

                               FORM OF ASSIGNMENT

     FOR VALUE RECEIVED, the undersigned hereby sells, assigns, and transfers
all the rights of the undersigned under the within Warrant, with respect to the
number of shares of Common Stock covered thereby set forth hereinbelow, to:

<TABLE>
<CAPTION>
Name of Assignee   Address   No. of Shares
----------------   -------   -------------
<S>                <C>       <C>

</TABLE>

, and hereby irrevocably constitutes and appoints ___________________________ as
agent and attorney-in-fact to transfer said Warrant on the books of the
within-named corporation, with full power of substitution in the premises.

Dated: ________________, ____

In the presence of

-------------------------------------

                                        Name:
                                              ----------------------------------

                                        Signature:
                                                   -----------------------------
                                        Title of Signing Officer or Agent (if
                                        any):

                                        ----------------------------------------
                                        Address:
                                                 -------------------------------

                                        ----------------------------------------

                                        Note: The above signature should
                                              correspond exactly with the name
                                              on the face of the within Warrant.<PAGE>

                                                                    Exhibit 10.4

                         COMMON STOCK PURCHASE AGREEMENT

     This COMMON STOCK PURCHASE AGREEMENT (this "AGREEMENT") is entered into as
of the 24th day of March, 2006, by and between Biotech Shares Ltd., an entity
organized and existing under the laws of the Isle of Man (the "INVESTOR"), and
Idera Pharmaceuticals, Inc., a corporation organized and existing under the laws
of the State of Delaware (the "COMPANY").

     WHEREAS, the Investor and the Company (the "PARTIES") desire that, upon the
terms and subject to the conditions and limitations set forth herein, the
Company may issue and sell to the Investor, from time to time as provided
herein, and the Investor shall purchase from the Company, up to US$9,750,000 of
shares of Common Stock (as defined below) of the Company;

     WHEREAS, in consideration for the Investor's execution and delivery of, and
its performance of its obligations under, this Agreement, the Company is
concurrently with the execution of this Agreement issuing to the Investor
warrants to purchase 6,093,750 shares of Common Stock at an exercise price of
$0.74 per share in the form of Exhibit A hereto, which warrants shall be
exercisable at any time during the five-year period commencing September 24,
2006 (the "WARRANTS");

     WHEREAS, the Parties hereto are concurrently entering into a Registration
Rights Agreement in the form of Exhibit B hereto (the "REGISTRATION RIGHTS
AGREEMENT") pursuant to which the Company shall register the Common Stock issued
and sold to the Investor under this Agreement and issuable pursuant to the
Warrants upon the terms and subject to the conditions set forth therein; and

     WHEREAS, to assure payment of the purchase price for the Common Stock and
the delivery of the certificates for the Common Stock purchased by the Investor
when and if the Company elects in its sole discretion to sell such Common Stock
to the Investor, the Investor is causing concurrently with the execution of this
Agreement First National Bank of Lebanon (the "INVESTOR BANK") to issue a letter
of credit through JP Morgan Chase Bank, N.A. (the "CONFIRMING BANK") in the form
attached hereto as Exhibit C (the "LOC") on behalf of the Company.

     NOW, THEREFORE, the Parties hereto agree as follows:

     1. PURCHASE OBLIGATION. The Investor, intending to be legally bound, hereby
irrevocably agrees to purchase from the Company shares of Common Stock with an
aggregate purchase price of up to US$9,750,000 (the "MAXIMUM PURCHASE PRICE"),
if and when the Company exercises its right to sell to the Investor such shares
of Common Stock in accordance with Section 3 of this Agreement.

     2. INITIAL CLOSING

          (a) The closing of the execution and delivery of this Agreement shall
take place at the offices of Wilmer Cutler Pickering Hale and Dorr LLP, 60 State
Street, Boston, Massachusetts at 10:00 a.m. local time on the date of this
Agreement (the "CLOSING").

          (b) At the Closing:

                                       1

<PAGE>

               (i) The Company and the Investor shall execute and deliver this
Agreement;

               (ii) The Company and the Investor shall execute and deliver the
Registration Rights Agreement;

               (iii) The Investor shall cause the delivery of the LOC by the
Investor Bank and the Confirming Bank (the "Banks"); and

               (iv) The Company shall execute and deliver to the Investor the
Warrants.

     3. SUBSEQUENT CLOSINGS

          (a) At any time, on or after June 24, 2006 and prior to December 15,
2006, the Company, may, in its sole discretion, deliver to the Investor one or
more written notices in the form attached hereto as Exhibit D (each, a "PURCHASE
NOTICE") specifying

               (i) The dollar amount of Common Stock (with respect to each
Purchase Notice, the "PURCHASE AMOUNT") it elects to sell to the Investor on the
closing date for such sale;

               (ii) The closing date for such sale (which date shall be 15 days
after the effectiveness of the Purchase Notice);

               (iii) The number of shares of Common Stock to be issued on such
closing date; and

               (iv) The price per share of Common Stock used to calculate the
number of shares of Common Stock to be issued on such closing date.

If the Purchase Notice involves a Purchase Amount, which when aggregated with
the Purchase Amount of Common Stock previously sold to the Investor hereunder
exceeds $2,500,000, the Company shall confirm in such Purchase Notice that a
registration statement (the "PRE-ISSUANCE REGISTRATION STATEMENT") covering the
resale of the shares of Common Stock to be issued on such closing date has been
declared and is effective and that the certificates representing such shares
shall not bear a restricted securities legend.

Notwithstanding the foregoing,

               (A) the Company may not issue more than three Purchase Notices;

               (B) the closing date for a Purchase Notice may not occur within
45 days of the closing date for another Purchase Notice hereunder;

               (C) the Purchase Amount that the Company may elect to sell to the
Investor under a single Purchase Notice on any closing date shall not exceed
$4,000,000;

                                       2

<PAGE>

               (D) the aggregate Purchase Amount that the Company may elect to
sell to the Investor under all Purchase Notices may not exceed the Maximum
Purchase Price; and

               (E) any Purchase Amount not sold under this Agreement on or
before December 31, 2006 will lapse if not used.

          (b) The number of shares of Common Stock to be issued in connection
with a Purchase Notice shall be determined by dividing (1) the Purchase Amount
specified in the Purchase Notice by (ii) the greater of (A) $0.64 and (B) 80% of
the volume-weighted average of the Closing Prices (as defined below) of the
Common Stock for the five consecutive Trading Days (as defined below)
immediately preceding the date that the Company sends such Purchase Notice to
the Investor.

          (c) The Investor agrees that payment of the full Purchase Amount with
respect to a Purchase Notice shall be made on the date specified in the Purchase
Notice (the "PAYMENT DATE") through the Letter of Credit. Upon receipt by the
Confirming Bank of the information required by the Letter of Credit, the
Confirming Bank shall wire to the Company's designated account on the Payment
Date the Purchase Amount specified by the Company.

          (d) Notwithstanding the foregoing, the Investor shall have no
obligation hereunder to purchase any shares of Common Stock if the Purchase
Amount of such shares, when aggregated with the Purchase Amount of Common Stock
previously sold to the Investor under this Agreement, exceeds $2,500,000 unless
the Pre-Issuance Registration Statement has been declared and is effective and
the certificates representing such shares will not bear a restricted securities
legend.

          (e) The Investor covenants that during period from the date hereof
until the earlier of (i) December 31, 2006 and (ii) the date the Company is no
longer entitled to sell any additional shares of Common Stock to the Investor
under this Agreement (because the Company has sold the full US$9,750,000
contemplated by this Agreement or otherwise), neither the Investor nor any of
its affiliates nor any entity managed or controlled by the Investor will ever
enter into or execute or cause any person to enter into or execute any "short
sale" of any shares of Common Stock.

          (f) Certain Definitions.

               (i) "CLOSING PRICE" of the Common Stock on any date means the
last reported sales price or, in case no such reported sale takes place on such
date, the average of the reported closing bid and ask prices on the principal
trading market for the Common Stock. If no such prices are available, the
Closing Price shall be the fair value of one share of Common Stock as determined
in good faith by the Board of Directors.

               (ii) "COMMON STOCK" means the common stock, US$0.001 par value,
of the Company as it exists on the date of this Agreement, and any shares of any
class or classes of capital stock of the Company resulting from any
reclassification or reclassifications thereof and which have no preference in
respect of dividends or of amounts payable in the event of any voluntary or
involuntary liquidation, dissolution or winding-up of the Company and which are
not subject to redemption by the Company.

                                       3

<PAGE>

               (iii) "TRADING DAY" means, with respect to any security, each
Monday, Tuesday, Wednesday, Thursday and Friday, other than any day on which
securities are not generally traded on the principal exchange or market on which
such security is traded.

     4. REPRESENTATIONS AND WARRANTIES. The Investor hereby acknowledges,
represents, warrants and agrees as follows:

          (a) The Investor understands that the offering and sale outside the
United States of the Common Stock, the Warrants and the Common Stock issuable
upon exercise of the Warrants (the "OFFERING ") is intended to be exempt from
registration under the U.S. Securities Act of 1933, as amended (the "SECURITIES
ACT"), in accordance with Regulation S under the Securities Act ("REGULATION
S"), based, in part, upon the representations, warranties and agreements of the
Investor contained in this Agreement and of the shareholders of the Investor
contained in the representation letters that the Company may obtain from time to
time from the shareholders of the Investor;

          (b) The Investor and the Investor's attorney, accountant, Investor
representative and/or tax advisor, if any (collectively, the "ADVISORS"), have
received all documents requested by the Investor and the Investor and its
Advisors, if any, have carefully reviewed them and understand the information
contained therein prior to the execution of this Agreement;

          (c) None of the U.S. Securities and Exchange Commission, any state
securities commission or any other regulatory authority (foreign or otherwise)
has approved the Common Stock, the Warrants or any of the shares of Common Stock
issuable upon exercise of the Warrants, or passed upon or endorsed the merits of
the Offering;

          (d) The Investor and the Advisors, if any, have had a reasonable
opportunity to ask questions of and receive answers from a person or persons
acting on behalf of the Company concerning the Offering and the business,
financial condition, results of operations and prospects of the Company, and all
such questions have been answered to the full satisfaction of the Investor and
the Advisors, if any;

          (e) The Investor has taken no action which would give rise to any
claim by any person against the Company for brokerage commissions, finders' fees
or the like relating to this Agreement or the transactions contemplated hereby;

          (f) The Investor, either alone or together with its Advisors, if any,
have such knowledge and experience in financial, tax, and business matters, and,
in particular, investments in securities, so as to enable them to utilize the
information made available to them in connection with the Offering to evaluate
the merits and risks of an investment in the Common Stock, the Warrants and the
Company and to make an informed investment decision with respect thereto;

          (g) The Investor is not relying on the Company, or any of its agents
or any of their respective employees or agents with respect to the legal, tax,
economic and related considerations of an investment in the Common Stock, the
Warrants or the shares of Common Stock issuable upon exercise of the Warrants,
and the Investor has relied on the advice of, or has consulted with, only its
own Advisors;

                                       4

<PAGE>

          (h) The Investor is acquiring the Common Stock, the Warrants and the
Common Stock issuable upon exercise of the Warrants solely for such Investor's
own account for investment and not with a view to resale or distribution
thereof, in whole or in part. Except for arrangements with shareholders of the
Investor as provided in the organizational documents of the Investor, the
Investor has no agreement or arrangement, formal or informal, with any person to
sell or transfer all or any part of the Common Stock, the Warrants or the shares
of Common Stock issuable upon exercise of the Warrants, and the Investor has no
plans to enter into any such agreement or arrangement;

          (i) The purchase of the Common Stock, the Warrants and the Common
Stock issuable upon exercise of the Warrants represents high risk capital and
the Investor is able to afford an investment in a speculative venture having the
risks and objectives of the Company. The Investor must bear the substantial
economic risks of the investment in the Common Stock, the Warrants and the
Common Stock issuable upon exercise of the Warrants indefinitely because none of
the Common Stock, the Warrants or the shares of Common Stock issuable upon
exercise of the Warrants, may be sold, hypothecated or otherwise disposed of
unless (i) such securities are registered under the Securities Act, (ii) an
exemption from such registration is available in a transaction not subject to
the registration requirements of the Securities Act or (iii) in accordance with
Regulation S. The Company has agreed to file a registration statement to
register the resale of the shares of Common Stock to be sold pursuant to this
Agreement and the shares of Common Stock issuable upon exercise of the Warrants
under the Securities Act pursuant to the Registration Rights Agreement and has
agreed in Section 3(a) and 3(d) that it cannot issue and sell more than
$2,500,000 of Common Stock to the Investor hereunder unless the shares of Common
Stock to be issued to the Investor have been registered for resale pursuant to
the Pre-Issuance Registration Statement;

          (j) The Investor has adequate means of providing for such Investor's
current financial needs and foreseeable contingencies and has no need for
liquidity of the investment in the Common Stock, the Warrants and the shares of
Common Stock issuable upon exercise of the Warrants for an indefinite period of
time;

          (k) The Investor is aware that an investment in the Common Stock, the
Warrants and the Common Stock issuable upon exercise of the Warrants involves a
number of very significant risks and has carefully read and considered the
matters set forth under the caption "Risks Factors" and other risk factors of
the Company that are referenced in the most recent Quarterly Report on Form 10-Q
filed by the Company with the SEC;

          (l) The Investor is not a U.S. person (as defined in Securities Act
Rule 902(k)) and is not acquiring the Common Stock, the Warrants or the shares
of Common Stock issuable upon exercise of the Warrants, for the account or
benefit of any U.S. person. None of the Investor's shareholders are a U.S.
person.

          (m) The Investor represents it is duly organized, validly existing and
in good standing under the laws of the jurisdiction of its organization; the
consummation of the transactions contemplated hereby is authorized by, and will
not result in a violation of any applicable law or its charter or other
organizational documents; it has full power and authority to execute and deliver
this Agreement and all other related agreements or certificates and to carry out
the provisions hereof and thereof and to purchase and hold the Common Stock, the
Warrants and the Common Stock issuable upon exercise of the Warrants; the
execution and delivery of this

                                       5

<PAGE>

Agreement has been duly authorized by all necessary action; and this Agreement
has been duly executed and delivered on behalf of such entity and is a legal,
valid and binding obligation of such entity. The execution and delivery of this
Agreement will not violate or be in conflict with any order, judgment,
injunction, agreement or controlling document to which the Investor is a party
or by which it is bound;

          (n) The Investor represents to the Company that any information which
the Investor has heretofore furnished or is furnishing herewith to the Company
is complete and accurate and may be relied upon by the Company in determining
the availability of an exemption from registration under U.S. Federal securities
laws and applicable laws of states and foreign jurisdictions in connection with
the Offering;

          (o) Within five days after receipt of a request from the Company, the
Investor will provide such information and deliver such documents as may
reasonably be necessary to comply with any and all laws and ordinances to which
the Company is subject, including all information regarding the Investor that
the Company requests in connection with the registration statements to be filed
pursuant to the Registration Rights Agreement;

          (p) In evaluating its investment hereby in the Company, the Investor
has not relied upon any representation or other information (oral or written)
provided to the Investor or its Advisors by or on behalf of the Company other
than the information contained in the Company's filings with the U.S. Securities
and Exchange Commission;

          (q) The Investor acknowledges that the Company will not deliver a
Purchase Notice and seek to issue and sell shares of Common Stock hereunder
until such time as the number of authorized shares of Common Stock of the
Company is increased and that the Company plans to seek stockholder approval of
an increase in the number of authorized shares of Common Stock at its next
annual meeting of stockholders;

          (r) As of the date hereof, none of the Common Stock to be issued
hereunder, Warrants or the shares of Common Stock issuable upon exercise of the
Warrants have been registered under The U.S. Securities Act of 1933, as amended,
or under any applicable securities laws of any state or foreign jurisdiction and
such securities are being offered and sold in reliance on exemptions from the
registration requirements of said Act and such laws. The securities are subject
to restrictions on transferability and resale and may not be transferred or
resold except as permitted under said Act and such laws pursuant to registration
or exemption therefrom;

          (s) Each certificate representing shares of Common Stock or Common
Stock issuable upon exercise of the Warrants, and the Warrants shall bear a
legend substantially in the following form:

               "These securities have not been registered under the Securities
               Act of 1933. They may not be offered or transferred by sale,
               assignment, pledge or otherwise unless (i) a registration
               statement for the securities under the Securities Act of 1933 is
               in effect or (ii) the corporation has received an opinion of
               counsel, which opinion is satisfactory to the corporation, to the
               effect that such registration is not required under the
               Securities Act of 1933 or (iii) such offer or transfer is made in
               accordance

                                       6

<PAGE>

               with the provisions of Regulation S under the Securities Act of
               1933. Hedging transactions involving these securities may not be
               conducted unless in compliance with the Securities Act of 1933."

     Notwithstanding the foregoing, no certificate representing shares of Common
Stock issued pursuant to this Agreement following the effectiveness of the
Pre-Issuance Registration Statement which are covered by such Registration
Statement shall bear such legend without the prior written consent of the
Investor.

          (t) The Investor hereby confirms, and within five days after receipt
of a request from the Company, shall confirm, that in the event it proposes to
transfer any Common Stock issued to it under Section 3 or upon exercise of the
Warrants it shall comply with all requirements of the Securities Act applicable
to such transfer, including without limitation the requirement of delivering a
current prospectus in a timely manner in connection with the transfer.

     5. IRREVOCABILITY; BINDING EFFECT. The Investor hereby acknowledges and
agrees that the agreements hereunder, including the agreement to purchase shares
of Common Stock if and when the Company exercises its right to sell to the
Investor such shares of Common Stock in accordance with Section 3, are
irrevocable by the Investor, except as required by applicable law, and that this
Agreement shall be binding upon and inure to the benefit of the Parties and
their administrators, successors, legal representatives, and permitted assigns.

     6. MODIFICATION. Except as expressly permitted herein, this Agreement shall
not be modified or waived except by an instrument in writing signed by the Party
against whom any such modification or waiver is sought. The Company may
terminate this Agreement at any time, without consent of the Investor, without
penalty.

     7. NOTICES. Any notice or other communication required or permitted to be
given hereunder shall be in writing and shall be mailed by certified mail,
return receipt requested, or by a reputable overnight delivery service or shall
be delivered against receipt to the Party to whom it is to be given (a) if to
the Company, at the address set forth above, or (b) if to the Investor, at the
address set forth on the signature page hereof (or, in either case, to such
other address as the Party shall have furnished in writing in accordance with
the provisions of this Section 7). Any notice or other communication given by
certified mail shall be deemed given at the time of certification thereof and
any notice or other communication given by overnight delivery service shall be
deemed given two business days after deposit with the courier; provided,
however, that a notice changing a Party's address shall be deemed given at the
time of receipt thereof.

     8. ASSIGNABILITY. This Agreement and the rights, interests and obligations
hereunder are not transferable or assignable by the Investor.

     9. APPLICABLE LAW. This Agreement shall be governed by and construed in
accordance with the laws of the Commonwealth of Massachusetts in the United
States without reference to the principles thereof relating to the conflict of
laws.

     10. BLUE SKY QUALIFICATION. The purchase of the Common Stock and the
Warrants under this Agreement is expressly conditioned upon the exemption from
qualification of the offer and sale of the Common Stock and Warrants from
applicable U.S. Federal securities laws and the

                                       7

<PAGE>

applicable laws of states and foreign jurisdictions. The Company shall not be
required to qualify as a foreign corporation or execute a general consent to
service of process in any jurisdiction and, should qualification or execution of
a general consent be necessary, the Company shall be released from any and all
obligations to maintain its offer, and may rescind any sale contracted, in the
jurisdiction.

     11. USE OF PRONOUNS. All pronouns and any variations thereof used herein
shall be deemed to refer to the masculine, feminine, neuter, singular or plural
as the identity of the person or persons referred to may require.

     12. CONFIDENTIALITY. The Investor acknowledges and agrees that any
information or data the Investor has acquired from or about the Company, not
otherwise properly in the public domain, was received in confidence. The
Investor agrees not to divulge, communicate or disclose, except as may be
required by law or for the performance of this Agreement, or use to the
detriment of the Company or for the benefit of any other person or persons, or
misuse in any way, any confidential information of the Company, including any
scientific, technical, trade or business secrets of the Company and any
scientific, technical, trade or business materials that are treated by the
Company as confidential or proprietary, including, but not limited to, ideas,
discoveries, inventions, developments and improvements belonging to the Company
and confidential information obtained by or given to the Company about or
belonging to third parties.

     13. MISCELLANEOUS.

          (a) This Agreement, together with the Registration Rights Agreement
and the Warrants, constitute the entire agreement between the Investor and the
Company with respect to the subject matter hereof, except for any confidential
disclosure agreement between the Investor and the Company, and supersede all
prior oral or written agreements and understandings, if any, between the Parties
relating to the subject matter hereof, except for any confidential disclosure
agreement between the Investor and the Company.

          (b) The Investor's representations and warranties made in this
Agreement shall survive the execution and delivery hereof and delivery of the
Common Stock, the Warrants and the Common Stock issuable upon exercise of the
Warrants.

          (c) Each of the Parties hereto shall pay its own fees and expenses
(including the fees of any attorneys, accountants, appraisers or others engaged
by such Party) in connection with this Agreement and the transactions
contemplated hereby whether or not the transactions contemplated hereby are
consummated.

          (d) This Agreement may be executed in one or more counterparts each of
which shall be deemed an original, but all of which shall together constitute
one and the same instrument.

          (e) Each provision of this Agreement shall be considered separable
and, if for any reason any provision or provisions hereof are determined to be
invalid or contrary to applicable law, such invalidity or illegality shall not
impair the operation of or affect the remaining portions of this Agreement.

                                       8

<PAGE>

          (f) Paragraph titles are for descriptive purposes only and shall not
control or alter the meaning of this Agreement as set forth in the text.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       9

<PAGE>

IN WITNESS WHEREOF, the Parties have caused this Common Stock Purchase Agreement
to be duly executed as of the date first set forth above..

                                        IDERA PHARMACEUTICALS, INC.

                                        By: /s/ Sudhir Agrawal
                                            ------------------------------------
                                        Name: Sudhir Agrawal
                                        Title: Chief Executive Officer

BIOTECH SHARES LTD.

By: /s/ Oussama Salam
    ---------------------------------
Name: Oussama Salam
Title: Director

Address: St. James's Chambers
         64A Athol Street
         Isle of Man IM1 1JE

                                       10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]